Joanna Smart
Direktor/Vorstandsmitglied bei Verso Biosense Group Ltd.
Profil
Joanna Smart is currently a Director at Verso Biosense Group Ltd.
Prior to this, she was the Executive Chairman and CEO at Oxford Cancer Biomarkers Ltd.
Aktive Positionen von Joanna Smart
| Unternehmen | Position | Beginn |
|---|---|---|
Verso Biosense Group Ltd.
 Verso Biosense Group Ltd. Financial ConglomeratesFinance Verso Biosense Group Ltd. is a British dormant company that was founded in 2016. The private company is based in Milton, UK. and has subsidiaries in United Kingdom. | Direktor/Vorstandsmitglied | 09.04.2021 |
Ehemalige bekannte Positionen von Joanna Smart
| Unternehmen | Position | Ende |
|---|---|---|
Oxford Cancer Biomarkers Ltd.
 Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Verso Biosense Group Ltd.
Verso Biosense Group Ltd. Financial ConglomeratesFinance Verso Biosense Group Ltd. is a British dormant company that was founded in 2016. The private company is based in Milton, UK. and has subsidiaries in United Kingdom. | Finance |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Health Services |
